Multi-omics analysis reveals CLIC1 as a therapeutic vulnerability of gliomas.
Wang C, He Z.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2023.1279370 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för TAK-733. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
15 hitsCombining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres.
Essien EI, Hofer TP, Atkinson MJ, Anastasov N.
Cells · research-article; journal article · DOI 10.3390/cells11050775Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I.
Wang W, Cui XW, Gu YH, Wei CJ, Li YH, Ren JY, Chung MH, Aimaier RH, Zhang HB, Li QF, Wang ZC.
J Invest Dermatol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jid.2021.07.164MEK1 Inhibitor Combined with Irradiation Reduces Migration of Breast Cancer Cells Including miR-221 and ZEB1 EMT Marker Expression.
Anastasov N, Hirmer E, Klenner M, Ott J, Falkenberg N, Bao X, Mutschelknaus L, Moertl S, Combs S, Atkinson MJ, Schmid T.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12123760TAK733 attenuates adrenergic receptor-mediated cardiomyocyte hypertrophy via inhibiting ErkThr188 phosphorylation.
Lee CY, Lee J, Seo HH, Shin S, Kim SW, Lee S, Lim S, Hwang KC.
Clin Hemorheol Microcirc · journal article · DOI 10.3233/ch-180476TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells.
Jasek-Gajda E, Gajda M, Jasińska M, Litwin JA, Lis GJ.
Anticancer Res · journal article · DOI 10.21873/anticanres.12967TAK-733 inhibits inflammatory neointimal formation by suppressing proliferation, migration, and inflammation in vitro and in vivo.
Park JH, Kim SW, Cha MJ, Yoon N, Lee CY, Lee J, Seo HH, Shin S, Choi JW, Lee S, Lim S, Hwang KC.
Exp Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s12276-018-0052-yHigh-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1).
Peterson BG, Tan KW, Osa-Andrews B, Iram SH.
Pharmacol Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.phrs.2017.02.024A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S, Neuwirth R, Bózon V.
Invest New Drugs · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-016-0391-2MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.
de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, Azab AK.
Blood Cancer J · letter; research support, n.i.h., extramural · DOI 10.1038/bcj.2016.7Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.
Oncotarget · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.5949Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549.
Ishino S, Miyake H, Vincent P, Mori I.
Ann Nucl Med · research-article; journal article · DOI 10.1007/s12149-015-0984-4Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG.
Mol Cancer Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-13-1012Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A.
Mol Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1476-4598-11-22Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB, Zhou F.
Bioorg Med Chem Lett · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.bmcl.2011.01.071